RESEARCH ARTICLE
Serum Sphingolipid Variations Associate with Hepatic Decompensation and Survival in Patients with Cirrhosis Georgios Grammatikos1,2*, Nerea Ferreiròs3, Oliver Waidmann2, Dimitra Bon4, Sirkka Schroeter1,2, Alexander Koch1, Eva Herrmann4, Stefan Zeuzem2, Bernd Kronenberger2, Josef Pfeilschifter1
a11111
1 Pharmazentrum Frankfurt, Institut für Allgemeine Pharmakologie und Toxikologie, Frankfurt am Main, Germany, 2 Goethe University Hospital, Medizinische Klinik 1, Frankfurt am Main, Germany, 3 Pharmazentrum Frankfurt, Institut für klinische Pharmakologie, Goethe University Hospital, Frankfurt am Main, Germany, 4 Goethe University, Department of Medicine, Institute of Biostatistics and Mathematical Modelling, Frankfurt am Main, Germany * [email protected]
OPEN ACCESS Citation: Grammatikos G, Ferreiròs N, Waidmann O, Bon D, Schroeter S, Koch A, et al. (2015) Serum Sphingolipid Variations Associate with Hepatic Decompensation and Survival in Patients with Cirrhosis. PLoS ONE 10(9): e0138130. doi:10.1371/ journal.pone.0138130 Editor: Ashley Cowart, Medical University of South Carolina, UNITED STATES Received: July 14, 2015 Accepted: August 25, 2015
Abstract Background Sphingolipids constitute bioactive molecules with functional implications in liver homeostasis. Particularly, ablation of very long chain ceramides in a knockout mouse model has been shown to cause a severe hepatopathy.
Methods We aimed to evaluate the serum sphingolipid profile of 244 patients with cirrhosis prospectively followed for a median period of 228±217 days via mass spectrometry.
Published: September 18, 2015 Copyright: © 2015 Grammatikos et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Data Availability Statement: All relevant data are within the paper and its Supporting Information files. Funding: This work was supported by the German Research Foundation DFG (FOG784, PF361/5-2, PF361/7-1, GRK 1172, SFB 815 and SFB 1039). Competing Interests: The authors have declared that no competing interests exist. Abbreviations: MELD, model for end stage liver disease; Cer, ceramide; SL, sphingolipid; NAFLD, non-alcoholic fatty liver disease; HBV, hepatitis B virus; HCV, hepatitis C virus; dh, dihydro; CT,
Results We thereby observed a significant decrease of long and very long chain ceramides, particularly of C24ceramide, in patients with increasing severity of cirrhosis (p
Serum Sphingolipid Variations Associate with Hepatic Decompensation and Survival in Patients with Cirrhosis Georgios Grammatikos1,2*, Nerea Ferreiròs3, Oliver Waidmann2, Dimitra Bon4, Sirkka Schroeter1,2, Alexander Koch1, Eva Herrmann4, Stefan Zeuzem2, Bernd Kronenberger2, Josef Pfeilschifter1
a11111
1 Pharmazentrum Frankfurt, Institut für Allgemeine Pharmakologie und Toxikologie, Frankfurt am Main, Germany, 2 Goethe University Hospital, Medizinische Klinik 1, Frankfurt am Main, Germany, 3 Pharmazentrum Frankfurt, Institut für klinische Pharmakologie, Goethe University Hospital, Frankfurt am Main, Germany, 4 Goethe University, Department of Medicine, Institute of Biostatistics and Mathematical Modelling, Frankfurt am Main, Germany * [email protected]
OPEN ACCESS Citation: Grammatikos G, Ferreiròs N, Waidmann O, Bon D, Schroeter S, Koch A, et al. (2015) Serum Sphingolipid Variations Associate with Hepatic Decompensation and Survival in Patients with Cirrhosis. PLoS ONE 10(9): e0138130. doi:10.1371/ journal.pone.0138130 Editor: Ashley Cowart, Medical University of South Carolina, UNITED STATES Received: July 14, 2015 Accepted: August 25, 2015
Abstract Background Sphingolipids constitute bioactive molecules with functional implications in liver homeostasis. Particularly, ablation of very long chain ceramides in a knockout mouse model has been shown to cause a severe hepatopathy.
Methods We aimed to evaluate the serum sphingolipid profile of 244 patients with cirrhosis prospectively followed for a median period of 228±217 days via mass spectrometry.
Published: September 18, 2015 Copyright: © 2015 Grammatikos et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Data Availability Statement: All relevant data are within the paper and its Supporting Information files. Funding: This work was supported by the German Research Foundation DFG (FOG784, PF361/5-2, PF361/7-1, GRK 1172, SFB 815 and SFB 1039). Competing Interests: The authors have declared that no competing interests exist. Abbreviations: MELD, model for end stage liver disease; Cer, ceramide; SL, sphingolipid; NAFLD, non-alcoholic fatty liver disease; HBV, hepatitis B virus; HCV, hepatitis C virus; dh, dihydro; CT,
Results We thereby observed a significant decrease of long and very long chain ceramides, particularly of C24ceramide, in patients with increasing severity of cirrhosis (p
